BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34319025)

  • 1. A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.
    Mohamed M; Mohd Nafi SN; Jaafar H; Paiman NM
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2043-2047. PubMed ID: 34319025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam.
    Dang Cong T; Nguyen Thanh T; Nguyen Phan QA; Hoang Thi AP; Nguyen Tran BS; Nguyen Vu QH
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1135-1142. PubMed ID: 32334482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
    Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
    Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HER2 gene status and mRNA expression in immunohistochemistry 1+ breast cancer].
    Wu SF; Liu YY; Liu XD; Jiang Y; Luo YF; Cui QC; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):522-526. PubMed ID: 29996317
    [No Abstract]   [Full Text] [Related]  

  • 9. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients.
    Dehghani M; Keshavarz P; Talei A; Akrami M; Tahmasebi S; Safaie A; Ghanbari M
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):3027-3032. PubMed ID: 33112563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
    Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
    J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
    Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
    Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression.
    Misron NA; Looi LM; Nik Mustapha NR
    Asian Pac J Cancer Prev; 2015; 16(4):1553-8. PubMed ID: 25743830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
    Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
    Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
    Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.